Method for comprehensive extraction of eicosanoid containing EPA and ARA from phaeodactylum tricornutum and application

By extracting eicosanoic acid-like compounds of EPA and ARA from *Phaeodactylum tricornutum*, the problem of high-cost extraction of lipoxygenase in existing technologies has been solved, enabling the preparation of low-cost, natural anti-inflammatory active substances suitable for a variety of products and meeting safety standards.

CN121021291BActive Publication Date: 2026-02-03HUBEI ZAOLAN BIOTECHNOLOGY CO LTD
4 Cites 0 Cited by

Patent Information

Application Number
CN202511561254.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-10-29
Publication Date
2026-02-03
Estimated Expiration
2045-10-29

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively extract lipoxygen-like active substances with well-defined chemical structures and significant anti-inflammatory effects from algae, resulting in high costs.

Method used

Eicosanoids containing EPA and ARA were isolated, purified, and extracted from *Phaeodactylum tricornutum*. The extracts were prepared for use in anti-inflammatory drugs, functional foods, or cosmetics through centrifugation, freeze-drying, extraction, acidification, and solid-phase extraction.

Benefits of technology

It provides low-cost, naturally sourced anti-inflammatory active ingredients that meet FDA/EFSA safety standards and are suitable for use in anti-inflammatory drugs, post-operative inflammation relief foods, and soothing and repairing cosmetics, with a wide market applicability.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides a method and application for comprehensively extracting eicosanoid containing EPA and ARA from Phaeodactylum tricornutum, establishes a complete process chain of "algal culture-algal mud acquisition-ASE rapid extraction of microalgal oil-SPE enrichment-semi-preparation HPLC purification", the composition ratio of the anti-inflammatory mediators is clear, and the structure is identified by high performance liquid chromatography; the existing literatures and patents do not disclose that the algal strain can simultaneously enrich the combination of the above-mentioned various anti-inflammatory mediators. And the raw material of Phaeodactylum tricornutum is derived from marine diatoms which can be cultured on a large scale, there is no risk of pesticide residue of terrestrial plants, and there is no organic chlorine solvent in the production process, which meets the requirements of FDA / EFSA on natural marine source functional ingredients; can be simultaneously used for anti-inflammatory prescription drugs, postoperative inflammation relief food and soothing and repairing cosmetics, and has a wide market adaptation.
Need to check novelty before this filing date? Find Prior Art